Inhibitor Binding in the Human Renal Low- and High-Affinity Na+/Glucose Cotransporters
- 6 December 2007
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 324 (3), 985-991
- https://doi.org/10.1124/jpet.107.129825
Abstract
The kidney contains two Na+/glucose cotransporters, called SGLT2 and SGLT1, arranged in series along the length of the proximal tubule. The low-affinity transporter, SGLT2, is responsible for the reabsorption of most of the glucose in the kidney. There is recent interest in SGLT2 as a target for the treatment of type II diabetes using selective inhibitors based on the structure of the phenylglucoside, phlorizin (phloretin-2′-β-glucoside). In this study, we examined the inhibition of α-methyl-d-glucopyranose transport by phlorizin and a new candidate drug, sergliflozin-A [(2-[4-methoxyphenyl]methyl)phenyl β-d-glucopyranoside], in COS-7 cells expressing hSGLT1 and hSGLT2. Inhibition by phlorizin was competitive, with Ki values of 0.3 μM in hSGLT1 and 39 nM in hSGLT2. Inhibition by sergliflozin-A was also competitive, with Ki values of 1 μM in hSGLT1 and 20 nM in hSGLT2. Phloretin [3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone; the aglucone of phlorizin] was a less potent inhibitor, with IC50 values of 142 μM in hSGLT1 and 25 μM in hSGLT2. Site-directed mutagenesis of residues believed to be in the phlorizin binding site showed that only Cys610 is involved in inhibitor binding in the human transporters. Mutation of Cys610 in hSGLT1 to lysine resulted in an increased IC50 for all inhibitors. In contrast, mutagenesis of the analogous Cys615 in hSGLT2 produced the opposite effect, a decrease in IC50 for phlorizin and sergliflozin-A. The differences in the effects of the mutations between hSGLT1 and hSGLT2 suggest that this cysteine holds key residues in place rather than participating directly in inhibitor binding.Keywords
This publication has 33 references indexed in Scilit:
- Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose LevelJournal of Pharmacology and Experimental Therapeutics, 2006
- A 96-well automated method to study inhibitors of human sodium-dependent D-glucose transportMolecular and Cellular Biochemistry, 2005
- Membrane topology of loop 13–14 of the Na+/glucose cotransporter (SGLT1): A SCAM and fluorescent labelling studyBiochimica et Biophysica Acta (BBA) - Biomembranes, 2005
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Localization of the Na + -d-glucose cotransporter SGLT1 in the blood-brain barrierHistochemistry and Cell Biology, 2004
- SGLT as a therapeutic targetDrugs of the Future, 2004
- Expression of GFP-Tagged Low Affinity Na+-Dependent Glucose Transporter in Xenopus Oocytes and CHO Cells.The Japanese Journal of Physiology, 2002
- Common mechanisms of inhibition for the Na+/glucose (hSGLT1) and Na+/Cl−/GABA (hGAT1) cotransportersBritish Journal of Pharmacology, 2001
- Glycoside Binding and Translocation in Na + -Dependent Glucose Cotransporters: Comparison of SGLT1 and SGLT3The Journal of Membrane Biology, 2000
- The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.JCI Insight, 1994